LVMH 402.800 € (-2,30 %) 
PROSUS 35.850 € (+0,17 %) L'OREAL 376.050 € (-1,07 %) VINCI 110.800 € (-1,86 %) AXA 44.730 € (-0,73 %) HERMES INTL 1 331.500 € (-3,16 %) SANOFI 74.050 € (-1,61 %) DANONE 60.540 € (-1,37 %) BNP PARIBAS ACT.A 100.740 € (-2,93 %) SAINT GOBAIN 69.120 € (-1,73 %) AHOLD DEL 31.600 € (-1,22 %) AIRBUS 193.380 € (-1,08 %) AIR LIQUIDE 163.160 € (-1,26 %) SCHNEIDER ELECTRIC 285.750 € (-0,47 %) NEXITY 5.255 € (-3,58 %) ALTAREA 85.300 € (-0,70 %) WOLTERS KLUWER 68.160 € (-2,74 %) PERNOD RICARD 59.440 € (-1,13 %) 
SHELL PLC 41.315 € (-0,59 %) UBISOFT ENTERTAIN 5.308 € (-2,61 %) EUROFINS SCIENT. 76.440 € (-0,57 %) MYHOTELMATCH 0.125 € (+16,90 %) AKZO NOBEL 56.080 € (-0,74 %) CSG 15.432 € (-4,07 %) ALSTOM 15.280 € (-2,64 %) VINPAI 2.600 € (-18,75 %) CEGEDIM 10.500 € (-0,19 %) EXAIL TECHNOLOGIES 124.500 € (0,00 %) MAUREL ET PROM 8.270 € (0,00 %) GECINA 65.500 € (-1,43 %) 
SES 4.758 € (-3,25 %) VIVENDI SE 1.493 € (-2,61 %) ARCELORMITTAL SA 63.120 € (-3,69 %) ASM INTERNATIONAL 813.800 € (+2,91 %) DASSAULT SYSTEMES 20.560 € (-0,10 %) MICHELIN 33.080 € (-1,37 %) LEGRAND 135.800 € (-0,37 %) CHRISTIAN DIOR 369.200 € (-2,17 %) PHARMING GROUP 0.917 € (-2,28 %) EUTELSAT COMMUNIC. 1.753 € (-2,99 %) CAPGEMINI 104.350 € (-2,57 %) LAKEFRONT BIOTHER. 24.980 € (+0,16 %) 2CRSI 28.360 € (-1,39 %) HOPIUM 0.004 € (+2,94 %) EURAZEO 46.420 € (-0,85 %) HAFFNER ENERGY BSA 0.010 € (-20,83 %) CREDIT AGRICOLE 18.190 € (-2,23 %) EXOR NV 68.500 € (-4,06 %) MAAT PHARMA 1.630 € (-18,50 %) CORBION 22.660 € (+0,98 %) ADP 108.300 € (-0,37 %) ENGIE 24.030 € (-0,91 %) MERCIALYS 10.480 € (-2,24 %) BE SEMICONDUCTOR 186.650 € (+2,84 %) CATERING INTL SCES 21.800 € (+9,55 %) IMERYS 22.440 € (-0,88 %) BOUYGUES 43.380 € (-3,28 %) BRUNEL INTERNAT 7.220 € (-0,55 %) UMG 14.750 € (+0,07 %) ACOMO 23.000 € (-1,08 %) |
24/08/2026 15:45
EQS-Adhoc: QIAGEN N.V.: QIAGEN appoints Jonathan M. Pratt as Chief Executive OfficerEQS-Ad-hoc: QIAGEN N.V. / Key word(s): Personnel decisions / Executive Board/Strategic corporate decision Ad hoc Announcement according to Art. 17 Market Abuse Regulation
QIAGEN appoints Jonathan M. Pratt as Chief Executive Officer Venlo, the Netherlands, August 24, 2026 – QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announces that Jonathan M. Pratt has been appointed Chief Executive Officer, effective September 1, 2026. He brings to QIAGEN more than 25 years of international leadership experience across life sciences, laboratory technologies and healthcare. Jon Pratt most recently served as President and CEO of Filtration Group, leading the business through the completion of its sale to Parker-Hannifin Corporation in August 2026. He previously served as Senior Vice President of the Waters Division at Waters Corporation and as President of Beckman Coulter Life Sciences, a Danaher operating company, and held senior leadership positions at Pall Corporation. Throughout his career, he has led global businesses spanning analytical instruments, laboratory technologies, software, consumables, services and bioprocessing applications. His experience includes commercial execution, portfolio management, operations and organizational development in markets closely aligned with QIAGEN’s portfolio and customer workflows. He will also be proposed for shareholder approval as a Managing Director at an Extraordinary General Meeting planned for the fourth quarter of 2026. Thierry Bernard will step down as CEO and Managing Director and will support an orderly transition through the end of the year. QIAGEN has reaffirmed its outlook for the third quarter and full-year 2026. QIAGEN remains focused on delivering solid profitable growth by advancing its growth pillars, improving operating efficiency and allocating capital to the highest-return opportunities. As previously communicated, the Supervisory Board continues to evaluate opportunities, with independent financial and legal advisors, as part of its strategic review to create value for shareholders and other stakeholders relative to QIAGEN’s standalone business plan and long-term strategic objectives. QIAGEN N.V. Hulsterweg 82 5912 PL Venlo The Netherlands
Ad hoc ISIN: NL0015001WM6 Frankfurt Stock Exchange, Regulated Market (Prime Standard)
Contacts QIAGEN N.V. Corporate Communications John Gilardi, Tel: +49 2103 29 11711; pr@qiagen.com End of Inside Information 24-Aug-2026 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
2387768 24-Aug-2026 CET/CEST Source : Webdisclosure.com |
||||||||||||||||||||||||||||||||||||
Cotations différées d'au moins 15 minutes (Paris, Amsterdam, Bruxelles, Lisbonne).
Cotations à la clôture (Francfort, New-York, Londres, Zurich).
Flux de cotations : Euronext (Places Euronext et Cours des Devises).
Bourse : technologie Cote Boursière